title: Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients.
abstract: BACKGROUND
  Bisphosphonates may aid in treating and preventing bone loss promoted by chronic immunosuppressive treatment and secondary hyperparathyroidism in renal transplant (RT) patients. However, the effectiveness of bisphosphonates is compromised by poor patient compliance. The objective of the study was to compare the effects of once monthly ibandronate with those of weekly risedronate administration on bone mineral density (BMD) and renal function in RT patients.
  
  
  METHODS
  Sixty-nine patients were prospectively recruited who were at least 12 months post-RT and were treated with either oral ibandronate 150 mg monthly (n=35) or oral risedronate 35 mg weekly (n=34). At baseline and 1 year, creatinine, calcium, alkaline phosphatase, and i-parathyroid hormone were measured, and BMD was determined by dual-energy X-ray absorptiometry.
  
  
  RESULTS
  Group I consisted of 35 patients (28 women) treated with ibandronate who were of a mean age of 63±12 years. Group II consisted of 34 patients (30 women) treated with risedronate who were of a mean age of 64±10 years. Lumbar BMD was as follows: baseline T-score (group I vs. group II) of -1.7±0.8 versus -1.9±0.8 (P=NS); and annual T-score of -1.3±0.6 versus -1.4±0.8 (P=NS). After 1 year, lumbar BMD improved to reveal a T-score of -1.3±0.6 in the ibandronate group (P<0.01) and -1.4±0.8 in the risedronate group (P<0.01). Femoral BMD was as follows: baseline T-score (group I vs. group II) of -2.1±0.7 versus -2.2±0.6 (P=NS); and annual T-score of -1.8±0.9 versus -1.8±0.8 (P=NS). Cortical bone also improved in both groups, but results were not statistically significant. No changes in renal function and no adverse effects were observed.
  
  
  CONCLUSIONS
  In RT patients with low BMD, no difference in effects on BMD, renal function, or adverse effects were observed between monthly oral ibandronate and weekly oral risedronate administration.
authors: Departments of aNephrology and Renal Transplant bNuclear Medicine, Hospital Clinic, Barcelona cDepartment of Nephrology, Fundación Jimenez Díaz, Madrid, Spain dDepartment of Nuclear Medicine, Santa Maria Della Misericordia Hospital, Rovigo, Italy eDepartment of Cancer Imaging, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK.
authors: Ana
authors: A
authors: Sánchez-Escuredo
authors: David
authors: D
authors: Fuster
authors: Domenico
authors: D
authors: Rubello
authors: Africa
authors: A
authors: Muxí
authors: Ana
authors: A
authors: Ramos
authors: Francisco
authors: F
authors: Campos
authors: Maria Cristina
authors: MC
authors: Marzola
authors: Gary J
authors: GJ
authors: Cook
authors: Andrés
authors: A
authors: Tapias
authors: José-Vicente
authors: JV
authors: Torregrosa
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000068296:Risedronic Acid / Q000008:administration & dosage* / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D004164:Diphosphonates; D000068296:Risedronic Acid; D000077557:Ibandronic Acid